Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enfortumab vedotin plus pembrolizumab with or without platinum-gemcitabine versus chemotherapy in previously untreated advanced urothelial cancer
2019-004542-15Phase 3Active
- Sponsor
- Seagen Inc.
- Start
- Jun 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of enfortumab vedotin, pembrolizumab, gemcitabine, cisplatin and carboplatin in transitional cell carcinoma (TCC) and transitional cell carcinoma of the bladder (TCC) (3 arms), sponsored by Seagen Inc. Primary endpoint: Progression-free survival. Started Jun 2020; status: active.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on 2019-004542-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004542-15.